DiabetesJul 2, 2026

Female ob/ob mice do not lose muscle from semaglutide treatment

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Jul 3, 2026

Abstract

Semaglutide had minimal effects on skeletal muscle mass and strength in ob/ob mice.

Female ob/ob mice showed complete resistance to muscle mass loss induced by semaglutide.
Weight loss from semaglutide did not significantly impact muscle function in either sex.
These findings suggest that semaglutide may produce different effects based on sex.
Further research is needed to understand the molecular mechanisms behind these protective outcomes.

Simplified

Female C57BL/6 J mice are relatively resistant to weight gain, which complicates the study of sex-specific metabolic responses. So, we used ob/ob mice to examine semaglutide-induced weight loss in both sexes. We wanted to determine whether semaglutide-induced weight loss produces sex-specific effects on skeletal muscle mass and function in ob/ob mice. Semaglutide had minimal effects on skeletal muscle mass and strength in ob/ob mice. In particular, females were completely resistant to loss of muscle mass. These findings reveal that semaglutide exerts sex-specific effects, highlighting a need for further research into the molecular mechanisms driving these distinct protective outcomes.

Full Text

Full text is available at the source.

View Full Text ↗

Female ob/ob mice do not lose muscle from semaglutide treatment

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief